Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 465
- Registration Number
- NCT01535729
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
- Conditions
- Sclerosis, Systemic
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT01532869
A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01531647
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01524978
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Arizona Oncology, Tucson, Arizona, United States
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis
- Conditions
- Anemia, Kidney Disease, Chronic
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT01519947
- Locations
- 🇲🇽
Unidad De Dialisis La Loma S.C., Pureto Vallarta, Mexico
🇲🇽Clínica San Cosme Centro Especializado en el Tratamiento de Enfermedades Renales S.C, Aguascalientes, Mexico
🇲🇽Nefros Investigación S.C., Delegación Coyoacan, Mexico
A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 165
- Registration Number
- NCT01519960
- Locations
- 🇺🇸
Johns Hopkins Hospital - Pediatric Gastroenterology, Baltimore, Maryland, United States
🇺🇸Children's Hospital Boston-Harvard Medical School; Division of Gastoenterology, Boston, Massachusetts, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT01519921
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01519323
A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01519336
A Study of RO4917523 in Patients With Fragile X Syndrome
- Conditions
- Fragile X Syndrome
- Interventions
- Drug: RO4917523 0.5 mgDrug: RO4917523 1.5 mgDrug: Placebo
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT01517698